search
Back to results

RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms

Primary Purpose

Long COVID, Long Covid19, Long Covid-19

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
BrainHQ/Active Comparator Activity
BrainHQ
PASC CoRE
tDCS-active
tDCS-sham
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Long COVID focused on measuring PASC, Cognitive

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 1. See NCT05965752 for RECOVER-NEURO: Platform Protocol level inclusion criteria which applies to this appendix Exclusion Criteria: 1. See NCT05965752 for RECOVER-NEURO: Platform Protocol level exclusion criteria which applies to this appendix Additional Appendix (Sub-study) Level Exclusion Criteria: Presence of metal objects in the head or neck Skin disorders or skin-sensitive areas near tDCS stimulation locations that would interfere with electrode placement or increase the risk of stimulation-induced damage, at the investigator's discretion

Sites / Locations

  • All sites listed under NCT05965752

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Active Comparator

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

BrainHQ Active Comparator

BrainHQ

BrainHQ + PASC CoRE

Brain HQ + tDCS-active

Brain HQ + tDCS-sham

Arm Description

5 sessions/week at 30 min/session

5 sessions/week at 30 min/session

BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions at 1 hr/session

2.0 mA stimulation delivered for 30 min during each BrainHQ session

Inactive stimulation delivered for 30 min during each BrainHQ session

Outcomes

Primary Outcome Measures

Change in Everyday Cognition 2 (ECog2)
Everyday Cognition 2 (ECog2) is a self-report, 41-item questionnaire used to measure the participant's simple reaction time; respond when X happens and Choice reaction time; respond only if X happens.

Secondary Outcome Measures

Change in PROMIS-cognitive function - short form 8a (PROMIS-Cog) total score
The PROMIS-Cog is the PROMIS short form for the cognitive function domain and is a self-report, 8-item questionnaire targeting cognitive function in the past seven days.
Change on an objective neurocognitive battery scores
Change in Everyday Cognition 2 (ECog2)
Everyday Cognition 2 (ECog2) is a self-report, 41-item questionnaire used to measure the participant's simple reaction time; respond when X happens and Choice reaction time; respond only if X happens.
Characterize the intervention's safety as measured by the proportion of Serious Adverse Events

Full Information

First Posted
July 25, 2023
Last Updated
September 6, 2023
Sponsor
Duke University
search

1. Study Identification

Unique Protocol Identification Number
NCT05965739
Brief Title
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
Official Title
RECOVER-NEURO: A Platform Protocol for Evaluation of Interventions for Cognitive Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
September 1, 2023 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential interventions for PASC-mediated cognitive dysfunction. The hypothesis is that PASC-mediated declines in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on enhancing those domains. This design seeks to evaluate each intervention relative to the Active Comparator. The BrainHQ (alone) arm is important because the intervention is commercially available, accessible, relatively inexpensive, and does not require trained personnel to administer. BrainHQ has been also been proven effective in other studies of cognitive dysfunction such as studies in aging, mild cognitive impairment, traumatic brain injury, among others. The BrainHQ + PASC CoRE arm and the BrainHQ + tDCS arms are suspected to provide cognitive improvements beyond BrainHQ alone through different mechanisms. Both PASC CoRE and tDCS have extensive prior use and have demonstrated utility in improving aspects of cognitive function in other clinical settings..
Detailed Description
Participants will be randomized to one of the intervention appendices that are actively enrolling at the time of randomization. Intervention appendices may be added or removed according to adaptive design and/or emerging evidence. Various interventions will be studied. Participants will be randomized equally across the five arms: Active Comparator (video games) BrainHQ BrainHQ + PASC CoRE BrainHQ + tDCS-active BrainHQ + tDCS-sham

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Long COVID, Long Covid19, Long Covid-19
Keywords
PASC, Cognitive

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
To achieve blinding and an equitable randomization probability, a two-step randomization process will be used. The study will employ a simple (unstratified) randomization scheme. At the first stage, each participant will be assigned with equal probability to one of the intervention appendices for which the participant is eligible, after applying any intervention-specific safety exclusions. At the second stage, each participant will be assigned according to the specific appendix's randomization procedure. Participants will have an equal chance of being randomized into any of the intervention groups.
Masking
ParticipantCare ProviderInvestigator
Masking Description
Participants assigned to control will be considered part of pooled analyses if the intervention was active at the time of their enrollment and the participants were eligible to receive that intervention. This will result in approximately a 1:1 allocation ratio for any intervention to pooled control. Sites will be informed to which intervention appendix participants are randomized, but, when applicable, not whether the participants are allocated to the active intervention arm or control arm within that appendix. The participants and investigators will be blinded throughout the study, when possible. If open intervention appendices do not have the ability to pool controls but have independent controls, at the second stage participants will be randomized in a 1:1 ratio to intervention vs control inside the specific intervention appendix the participants were randomized to at the first stage of the randomization procedure.
Allocation
Randomized
Enrollment
315 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BrainHQ Active Comparator
Arm Type
Active Comparator
Arm Description
5 sessions/week at 30 min/session
Arm Title
BrainHQ
Arm Type
Experimental
Arm Description
5 sessions/week at 30 min/session
Arm Title
BrainHQ + PASC CoRE
Arm Type
Experimental
Arm Description
BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions at 1 hr/session
Arm Title
Brain HQ + tDCS-active
Arm Type
Experimental
Arm Description
2.0 mA stimulation delivered for 30 min during each BrainHQ session
Arm Title
Brain HQ + tDCS-sham
Arm Type
Placebo Comparator
Arm Description
Inactive stimulation delivered for 30 min during each BrainHQ session
Intervention Type
Other
Intervention Name(s)
BrainHQ/Active Comparator Activity
Intervention Description
BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
Intervention Type
Other
Intervention Name(s)
BrainHQ
Intervention Description
BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
Intervention Type
Other
Intervention Name(s)
PASC CoRE
Intervention Description
PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention with demonstrated efficacy in improving attention and executive functions, among other cognitive domains.
Intervention Type
Device
Intervention Name(s)
tDCS-active
Intervention Description
Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place. The device has a user-friendly interface and a large-button keypad, making it is easy to use at home.
Intervention Type
Device
Intervention Name(s)
tDCS-sham
Intervention Description
tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
Primary Outcome Measure Information:
Title
Change in Everyday Cognition 2 (ECog2)
Description
Everyday Cognition 2 (ECog2) is a self-report, 41-item questionnaire used to measure the participant's simple reaction time; respond when X happens and Choice reaction time; respond only if X happens.
Time Frame
Baseline to End of Intervention (EOI) (Day 70)
Secondary Outcome Measure Information:
Title
Change in PROMIS-cognitive function - short form 8a (PROMIS-Cog) total score
Description
The PROMIS-Cog is the PROMIS short form for the cognitive function domain and is a self-report, 8-item questionnaire targeting cognitive function in the past seven days.
Time Frame
Baseline, EOI (Day 70), End of Study (EOS) (Day 160)
Title
Change on an objective neurocognitive battery scores
Time Frame
Baseline, EOI (Day 70), EOS (Day 160)
Title
Change in Everyday Cognition 2 (ECog2)
Description
Everyday Cognition 2 (ECog2) is a self-report, 41-item questionnaire used to measure the participant's simple reaction time; respond when X happens and Choice reaction time; respond only if X happens.
Time Frame
Baseline, EOS (Day 160)
Title
Characterize the intervention's safety as measured by the proportion of Serious Adverse Events
Time Frame
Baseline to EOS (Day 160)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. See NCT05965752 for RECOVER-NEURO: Platform Protocol level inclusion criteria which applies to this appendix Exclusion Criteria: 1. See NCT05965752 for RECOVER-NEURO: Platform Protocol level exclusion criteria which applies to this appendix Additional Appendix (Sub-study) Level Exclusion Criteria: Presence of metal objects in the head or neck Skin disorders or skin-sensitive areas near tDCS stimulation locations that would interfere with electrode placement or increase the risk of stimulation-induced damage, at the investigator's discretion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kanecia Zimmerman, MD PhD
Organizational Affiliation
Duke University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Daniel Laskowitz, MD MHS
Organizational Affiliation
Duke University
Official's Role
Study Chair
Facility Information:
Facility Name
All sites listed under NCT05965752
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
The investigators will share the summary of results on the study website: https://recovercovid.org/
Links:
URL
http://recovercovid.org/
Description
Related Info

Learn more about this trial

RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms

We'll reach out to this number within 24 hrs